Dr. Moore on the NOVA Trial for Ovarian Cancer

Kathleen Moore, MD
Published: Wednesday, Mar 15, 2017



Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

The NOVA trial aimed to determine whether the PARP inhibitor niraparib improves progression-free survival, with other endpoints being overall survival, time to first subsequent therapy, chemotherapy-free interval, and other quality-of-life measures.

This study allowed any patient with high-grade serous ovarian cancer to be split into 2 groups for independent studies.
 


Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

The NOVA trial aimed to determine whether the PARP inhibitor niraparib improves progression-free survival, with other endpoints being overall survival, time to first subsequent therapy, chemotherapy-free interval, and other quality-of-life measures.

This study allowed any patient with high-grade serous ovarian cancer to be split into 2 groups for independent studies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x